Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 6/2014

01-06-2014 | Gynecologic Oncology

Detection of E6-AP as a potential therapeutic target in cervical specimen of HPV-infected women

Authors: Peter Hillemanns, Matthias Jentschke, Thomas G. Evans, Philipp Soergel, Ralf Hass

Published in: Archives of Gynecology and Obstetrics | Issue 6/2014

Login to get access

Abstract

Purpose

Silencing of HPV oncogenes or their human host client proteins using topically applied small interfering RNA (siRNA) may be an attractive nonsurgical strategy for CIN treatment. An exploratory clinical investigation was designed to evaluate E6-AP mRNA expression levels in different stages of cervical intraepithelial neoplasia and during the menstrual cycle.

Methods

In 38 premenopausal women aged 18–45 years referred to colposcopy clinic, analysis of serum hormones, cervical smears for cytology and HPV DNA, cervical biopsy, p16 immunohistochemistry and E6-AP mRNA expression levels in cervical smears and biopsies were performed. The intra-subject variability in E6-AP mRNA expression of vaginal smears was assessed and compared to cervical biopsy specimens.

Results

RNA of sufficient quantity and quality was available for E6-AP expression analysis from 97 % of the collected cervical smears and from 56 % of the collected biopsy samples. The normalized RNA levels from cervical smears were approximately tenfold higher compared to biopsies. There was little influence by the phase of the menstrual cycle or by CIN stage. Real-time PCR showed that the expression level of E6-AP is in a range (<28 C t) that would allow for detection of at least 100-fold modulation by a therapeutic agent (based on an assay LOD of C t = 36).

Conclusions

Our findings suggest a potential therapeutic approach using E6-AP siRNA as a specific molecular target in cervical intraepithelial neoplasia.
Literature
1.
go back to reference Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P et al (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ(Clinical research ed) 337:a1284CrossRef Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P et al (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ(Clinical research ed) 337:a1284CrossRef
2.
go back to reference Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ et al (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204(2):169e1–169e8CrossRef Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ et al (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204(2):169e1–169e8CrossRef
3.
go back to reference Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H et al (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106(3):453–460PubMedCentralPubMedCrossRef Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H et al (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106(3):453–460PubMedCentralPubMedCrossRef
4.
go back to reference Young JL, Jazaeri AA, Darus CJ, Modesitt SC (2008) Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109(1):140–145PubMedCrossRef Young JL, Jazaeri AA, Darus CJ, Modesitt SC (2008) Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109(1):140–145PubMedCrossRef
5.
go back to reference Hillemanns P, Wang X, Hertel H, Andikyan V, Hillemanns M, Stepp H et al (2008) Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol 198(3):300e1–300e7CrossRef Hillemanns P, Wang X, Hertel H, Andikyan V, Hillemanns M, Stepp H et al (2008) Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol 198(3):300e1–300e7CrossRef
6.
go back to reference Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5):342–350PubMedCrossRef Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5):342–350PubMedCrossRef
7.
go back to reference Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103(5):368–383PubMedCentralPubMedCrossRef Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103(5):368–383PubMedCentralPubMedCrossRef
8.
go back to reference Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905–3910PubMedCentralPubMed Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905–3910PubMedCentralPubMed
9.
go back to reference Munger K, Phelps WC, Bubb V, Howley PH, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417–4421PubMedCentralPubMed Munger K, Phelps WC, Bubb V, Howley PH, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63:4417–4421PubMedCentralPubMed
10.
go back to reference Peralta-Zaragoza O, Bermudez-Morales VH, Madrid-Marina V (2010) RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer. Rev Invest Clin 62(1):63–80PubMed Peralta-Zaragoza O, Bermudez-Morales VH, Madrid-Marina V (2010) RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer. Rev Invest Clin 62(1):63–80PubMed
11.
go back to reference Chen XZ, Zhu KJ, Xu Y, Tang XY, Cai XZ, Zhang X et al (2010) RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp Dermatol 35(5):509–515PubMedCrossRef Chen XZ, Zhu KJ, Xu Y, Tang XY, Cai XZ, Zhang X et al (2010) RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp Dermatol 35(5):509–515PubMedCrossRef
12.
go back to reference Hengstermann A, D’Silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M (2005) Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 79(14):9296–9300PubMedCentralPubMedCrossRef Hengstermann A, D’Silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M (2005) Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 79(14):9296–9300PubMedCentralPubMedCrossRef
13.
go back to reference Tomaic V, Pim D, Banks L (2009) The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393(1):7–10PubMedCrossRef Tomaic V, Pim D, Banks L (2009) The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393(1):7–10PubMedCrossRef
14.
go back to reference Shai A, Pitot HC, Lambert PF (2010) E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res 70(12):5064–5073PubMedCentralPubMedCrossRef Shai A, Pitot HC, Lambert PF (2010) E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res 70(12):5064–5073PubMedCentralPubMedCrossRef
15.
go back to reference Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1(7):503–514PubMedCrossRef Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1(7):503–514PubMedCrossRef
16.
go back to reference Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY et al (2004) Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165(6):2177–2185PubMedCentralPubMedCrossRef Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY et al (2004) Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165(6):2177–2185PubMedCentralPubMedCrossRef
17.
go back to reference Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N et al (2010) Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 45(2):195–203PubMedCrossRef Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N et al (2010) Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 45(2):195–203PubMedCrossRef
18.
go back to reference Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr (2008) Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 111(2):356–364PubMedCrossRef Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr (2008) Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol 111(2):356–364PubMedCrossRef
19.
go back to reference Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh YK et al (2011) The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer 130(8):1925–1936PubMedCrossRef Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh YK et al (2011) The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer 130(8):1925–1936PubMedCrossRef
20.
go back to reference Yamato K, Egawa N, Endo S, Ui-Tei K, Yamada T, Saigo K et al (2011) Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Ther 18(8):587–597PubMedCrossRef Yamato K, Egawa N, Endo S, Ui-Tei K, Yamada T, Saigo K et al (2011) Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Ther 18(8):587–597PubMedCrossRef
Metadata
Title
Detection of E6-AP as a potential therapeutic target in cervical specimen of HPV-infected women
Authors
Peter Hillemanns
Matthias Jentschke
Thomas G. Evans
Philipp Soergel
Ralf Hass
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 6/2014
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-013-3120-5

Other articles of this Issue 6/2014

Archives of Gynecology and Obstetrics 6/2014 Go to the issue